Default company panoramic image

Perosphere Inc

Perosphere applies its proprietary delivery technology to approved drugs to enhance safety and efficacy or create new therapeutic uses.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Bedford, NY, USA
  • Currency USD
  • Employees 9
  • Website

Company Summary

The key competence at Perosphere is understanding the limitations of current therapeutic treatments and knowing how these treatments can be improved, or in certain cases redirected to another use, through the application of drug delivery technology. Perosphere selects drug candidates no longer protected by patents; however, incorporating Perosphere’s new technology into reformulations of those drugs enables patent protection.


  • Default avatar
    R. Timmis Ware
    General Counsel & VP of Legal Affairs

    Mr. Ware is an attorney in private practice. Mr. Ware is a former partner in the New York-based firm of Chadbourne & Parke LLP. He served as general counsel to several other companies where Dr. Steiner was the founder and CEO. Mr. Ware is a member of New York and Florida Bars.

  • Default avatar
    Solomon Steiner

    Dr. Steiner is the founder and CEO of three publicly-traded drug delivery companies: Biodel Inc. (Nasdaq: BIOD), MannKind Corp. (Nasdaq: MNKD), and Emisphere Technologies, Inc. (OTCQB: EMIS). Prior to joining Perosphere, Dr. Steiner served as Biodel’s Chairman, President and Chief Executive Officer from its inception in December 2003 through March of 2010.

  • Default avatar
    Edith Mathiowitz

    Dr. Mathiowitz is a tenured Professor of Medical Science and Engineering, and the Director of the Biotechnology graduate program in Brown's Department of Molecular Pharmacology, Physiology & Biotechnology. She was the founder of Spherics, Inc., the editor of The Encyclopedia of Controlled Drug Delivery Systems (1999), and serves as an editorial board member for five journals.

  • Default avatar
    James Costin
    CMO & VP of Medical Affairs

    Dr. Costin is the former Corporate Vice President of Scientific and Medical Affairs at Carter-Wallace, Inc. Dr. Costin worked on the development of Organidin, Soma, Rynatan, Felbatol, Taurolidine, Tenormin, Tenoretic, Nolvadex, Zestril, Vascor, among other drugs. He has an M.D. from Emory University School of Medicine.

  • Default avatar
    Philip Sussman

    Mr. Sussman is Managing Partner at The Channel Group, LLC. He served as CFO or senior management of public and private biotechnology companies including Perlegen Sciences, Inc., Memory Pharmaceuticals Corp., and Cadus Pharmaceutical Corp. He received a B.S. in Physics from Stony Brook University, an M.S. in Biotechnology from Manhattan College, and an S.M. in Management from the Sloan School of Management, MIT.

  • Default avatar
    Peter van Straelen
    VP of Business Development

    Mr. van Straelen is the former President of U.S. Operations and Executive Vice President for Worldwide Sales and Marketing for Akzo Nobel N.V.’s business unit, Diosynth, the largest manufacturer of heparin for pharmaceutical use. He received an M.Sc. in Biochemistry from the University of Amsterdam.

  • Default avatar
    Sasha Bakhru

    Dr. Bakhru is a Postdoctoral Fellow with Dr. Mathiowitz at Brown University, and winner of the 2008 Global MOOT Corp competition. Dr. Bakhru has co-authored over 20 publications, eight patents and one book chapter; his work has been published in 40 conference proceedings and abstracts. Dr. Bakhru received a B.S. in Biomedical Engineering from Columbia University, an M.S.E from Johns Hopkins University in Materials Science and a Ph.D. from CMU.

  • Default avatar
    Bryan Laulicht
    VP Research

    Dr. Laulicht is a Postdoctoral Fellow in the Harvard-MIT Health Sciences Technology program in the laboratories of Dr. Robert Langer and Dr. Jeffrey Karp. Dr. Laulicht has co-authored six publications, 11 patents and one book chapter. Dr. Laulicht received a BA in Biophysics from Columbia University where he was an I.I. Rabi Science Research Scholar and a PhD in Medical Science from Brown, for which he won the Joukowsky Outstanding Dissertation.


  • Default avatar
    R. Timmis Ware

Previous Investors

  • Default avatar
    Ogden CAP LLC
    Default avatar
    Steiner Ventures